Literature DB >> 1309450

Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinoma.

N Yuki1, N Hayashi, A Kasahara, H Hagiwara, K Katayama, H Fusamoto, T Kamada.   

Abstract

Sera from Japanese patients with chronic liver disease were tested for hepatitis B virus (HBV) markers and antibodies to hepatitis C virus (anti-HCV), and the results were correlated to the presence of hepatocellular carcinoma. In chronic non-A, non-B liver disease, anti-HCV prevalence was high both in patients with hepatocellular carcinoma (78/89, 88%) and without it (66/84, 79%), while previous HBV infection was more common in patients with hepatocellular carcinoma (65/89, 73%) than in those without it (46/84, 55%) (P less than 0.05). Coexistence of anti-HCV and antibodies to HBV was observed frequently in patients with hepatocellular carcinoma (56/89, 63%) compared with patients without it (39/84, 46%) (P less than 0.05). In chronic HBV carriers, anti-HCV was more common in patients with hepatocellular carcinoma (12/38, 32%) than in those without it (3/62, 5%) (P less than 0.01). These results suggest that infection with the two viruses may be a risk factor for more serious liver disease.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1309450     DOI： 10.1007/bf01308344

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  36 in total

1.  Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis.

Authors:  T Miyamura; I Saito; T Katayama; S Kikuchi; A Tateda; M Houghton; Q L Choo; G Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

3.  Natural history of hepatitis-associated antigen-positive chronic liver disease.

Authors:  F J Dudley; P J Scheuer; S Sherlock
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Hepatitis C-associated hepatocellular carcinoma.

Authors:  F Hasan; L J Jeffers; M De Medina; K R Reddy; T Parker; E R Schiff; M Houghton; Q L Choo; G Kuo
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

8.  Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.

Authors:  K Kiyosawa; Y Akahane; A Nagata; S Furuta
Journal:  Am J Gastroenterol       Date:  1984-10       Impact factor: 10.864

9.  Hepatitis B virus DNA detected in formalin-fixed liver specimens and its relation to serologic markers and histopathologic features in chronic liver disease.

Authors:  P J Rijntjes; T J Van Ditzhuijsen; A M Van Loon; U J Van Haelst; F B Bronkhorst; S H Yap
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

10.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.

Authors:  C Bréchot; M Hadchouel; J Scotto; M Fonck; F Potet; G N Vyas; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205
View more
  6 in total

1.  Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  S A Ahmad; M M Bilimoria; X Wang; F Izzo; P Delrio; P Marra; T P Baker; G A Porter; L M Ellis; J N Vauthey; S Dhamotharan; S A Curley
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

2.  High prevalence of hepatitis B and C viral markers in Japanese patients with hepatocellular carcinoma.

Authors:  N Tanaka; T Chiba; Y Matsuzaki; T Osuga; T Aikawa; K Mitamura
Journal:  Gastroenterol Jpn       Date:  1993-08

3.  HCV RNA and antibody to HCV core protein in Japanese patients with chronic liver disease.

Authors:  N Yuki; N Hayashi; H Hagiwara; T Takehara; A Kasahara; H Fusamoto; S Manabe; A Takamizawa; T Kamada; H Okayama
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

4.  Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma.

Authors:  J Bukh; R H Miller; M C Kew; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

5.  Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma.

Authors:  M J Tong; S Y Lee; S J Hwang; R L Co; P P Lai; D Chien; G Kuo
Journal:  West J Med       Date:  1994-02

6.  Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer.

Authors:  E Mita; N Hayashi; H Hagiwara; K Ueda; Y Kanazawa; A Kasahara; H Fusamoto; T Kamada
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.